Pharmacological Approaches to Combating Antimicrobial Resistance (R01)

The summary for the Pharmacological Approaches to Combating Antimicrobial Resistance (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Pharmacological Approaches to Combating Antimicrobial Resistance (R01)
	CFDA Number:	93.856
	CFDA Description:	Microbiology and Infectious Diseases Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-AI-07-025
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Apr 06, 2007
	Creation Date:	Apr 06, 2007
	Original Closing Date for Applications:	Oct 19, 2007
	Current Closing Date for Applications:	Information not provided
	Archive Date:	Nov 18, 2007
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$3,000,000
	Federal Grant Award Ceiling:	$500,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Independent school districts For profit organizations other than small businesses Private institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Public and State controlled institutions of higher education Small businesses Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) City or township governments
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Grant Description: -Purpose. The National Institute of Allergy and Infectious Diseases (NIAID) invites Research Project Grant (R01) applications from institutions/organizations that propose to apply pharmacokinetic and pharmacodynamic principles to studies on the prevention of emergence of antimicrobial drug resistance. This initiative is also intended to stimulate and strengthen collaborations between antimicrobial pharmacologists and infectious disease researchers to provide a synergistic, integrated approach that will form the basis for future clinical management of antimicrobial drug resistance. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. NIAID anticipates awarding a total of $3 million in FY 2008 to fund 5-8 awards for up to 4 years. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-07-025.html http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-07-025.html
Grant Announcement Contact: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Biomedical Prevention of HIV Research Education (R25); • Partnerships for Next Generation Biodefense Diagnostics (R01); • National Biocontainment Laboratories (NBLs) Operations Support Limited Competition (UC7); • Partnerships for Development of New Therapeutic Classes for Select Viral and Bacterial Pathogens (R0...; • Non-Antibiotic Selectable Markers for Biodefense (R21); • Partnerships to Improve Diagnosis and Treatment of Selected Drug-Resistant Healthcare-Associated Inf...; • Cooperative Research Partnerships for Biodefense (U01); • Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) [U54]; • Cooperative Research Partnerships for Biodefense and Emerging Infectious Diseases (U01)